Drug Induced Articles & Analysis
14 news found
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
"This funding supports further development of ENA001, which we believe has the potential to improve the standard of care in treating drug-induced respiratory depression with its unique mechanism of action as an agnostic respiratory stimulant." "The drug overdose epidemic in the United States continues to escalate and is growing in complexity ...
And it is used parenterally and short-term to relieve symptoms of osteoarthritis.D-Glucosamines for Research Use?As a drug delivery company that specializes in a range of formulation and drug delivery technologies, CD Bioparticles now offers a series of D-Glucosamines for research uses, such as CInd™ D-Glucosamine Hydrochloride, CInd™ D-Glucosamine Sulfate·2KCl, ...
Cell4Pharma’s ciPTEC technology is a human renal cell line that mimics the proximal tubule of the kidney, a common target for drug-induced kidney injury. The cells are currently used by researchers in monolayer culture as a preclinical screening tool by pharmaceutical developers to evaluate potential negative impacts to the kidney. ...
VeriSIM Life (VeriSIM), the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the acquisition of Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology to design more efficacious and safer therapeutics to achieve higher successes in ...
FDA Breakthrough Device Designation for the treatment of adult patients with moderate to severe OSA and Complete Concentric Collapse (CCC) of the soft palate in September; engaged in sprint discussions with FDA regarding the IDE study for CCC patients in the U.S., which Nyxoah hopes to commence in the second half of 2022 Received expanded CE Mark indication to treat CCC patients in October, thus ...
Patients, therefore, do not have to undergo a Drug-Induced Sleep Endoscopy (DISE) procedure to determine if they have CCC at the soft palate level prior to Genio® implantation. ...
Located in the epicenter of the US coronavirus pandemic, Lenox Hill Hospital will be using Medicomp’s TelePatch™ mobile cardiac telemetry (MCT) monitor to measure the heart’s electrical conduction for abnormalities in patients that have been prescribed certain medications in the treatment of COVID-19. Specifically, the drug therapies of chloroquine, ...
Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI disorders. Gut microbes express numerous proteins, including a family of bacterial β-glucuronidase enzymes capable of generating toxic metabolites of many common medications in the lower GI tract. Symberix is developing bacterial ...
Long-term objectives of the planned work include the development of a therapeutic adjunct to prevent adverse gastrointestinal events associated with essential drugs and the development of a microbiome-targeted drug to treat inflammatory bowel disease. ...
"Symberix is developing first-in-class adjunctive therapies to mitigate the debilitating lower GI side effects of pain, cancer and organ-transplant medicines by selectively inhibiting β-glucuronidase enzymes in gut bacteria with small-molecule, non-antibiotic drugs,” said Ward Peterson, Ph.D., CEO of Symberix. “Our approach could be as clinically and commercially ...
This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. Such lesions are rare but can have serious consequences for patients. ...
ByPoietis
"It enables our team to identify metabolomic safety biomarkers of drug-induced renal toxicity and the mechanisms by which these toxicities occur. This research will lead us to identifying at-risk patients and exploring the use of concomitantly administered medicines as protectants against drug-induced renal damage. It could have ...
(NYSE: A) today announced that Dr. Paul B. Watkins, international drug safety expert and director of the Hamner-University of North Carolina Institute for Drug Safety Sciences, has received an Agilent Thought Leader Award in recognition of his ongoing work developing integrated methods to predict drug-induced liver injury (DILI). ...